⚠️ For research and laboratory use only. Not for human or animal use.

Retatrutide

Name: Retatrutide 10mg GLP-1 GIP Glucagone | PepticoreAminos
Price: 129.00 EUR
Availability: InStock

129,00 €

Retatrutide è un peptide tri-agonista GLP-1/GIP/Glucagone, forma evoluta del tirzepatide, studiato per la ricerca su metabolismo e regolazione del peso corporeo.

3 products 5% OFF

122,55 € / each ~~129,00 €~~

6 products 8% OFF

118,68 € / each ~~129,00 €~~

10 products 12% OFF

113,52 € / each ~~129,00 €~~

Clear

Solvent not included. Add Bacteriostatic Water.

SKU: N/A Categories: Metabolic & Weight Loss, Lyophilized Peptides – Vials, Immune Support Brand: Pepticore Aminos

Laboratory analysis available (COA)Latest tested batch: PC-RET10-2610J — 10mg

Download latest COA

Pay With

Retatrutide — Tri-agonista GLP-1 / GIP / Glucagone

What is Retatrutide? Retatrutide (LY3437943) is a next-generation peptide belonging to the class of incretin mimetics. It acts simultaneously on three key hormonal receptors — GLP-1, GIP, and glucagon — aiming to synergistically modulate appetite, glucose metabolism, and energy expenditure. This triple mechanism positions it as the potential successor to tirzepatide, expanding the “dual agonist” concept into a new class of tri-agonists. All Pepticore Aminos products are strictly intended for research and laboratory use (Research Use Only).

How it works (GLP-1, GIP, Glucagon)

GLP-1 (glucagon-like peptide-1) sends satiety signals to the brain, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. It also helps reduce endogenous glucagon release, improving postprandial glucose control.

GIP (glucose-dependent insulinotropic polypeptide) enhances the insulin response after carbohydrate and fat intake, promoting glucose utilization for energy and reducing hepatic glucose production. Acting synergistically with GLP-1, it supports insulin sensitivity and lipid metabolism.

Glucagon in this context does not act as an insulin antagonist but as a regulator of energy metabolism. Its controlled activation increases lipolysis and fatty acid oxidation, promoting a higher resting energy expenditure and reduction of visceral fat. This triad of mechanisms makes retatrutide a unique research platform for studying complex metabolic balance.

🔬 Research Highlights

−24.2% mean body weight reduction after 48 weeks in adults with obesity (Phase 2, NEJM 2023)
−2.16 HbA1c points and ~17% weight loss in T2D after 36 weeks (Phase 2, Lancet 2023)
−81–82% liver fat reduction with normalization <5% in the MASLD substudy (Nature Medicine 2024)

Clinical Evidence (Phase 2)

Obesity without diabetes: In the New England Journal of Medicine study, retatrutide produced mean weight reductions of −22.8% (8 mg) and −24.2% (12 mg) after 48 weeks, along with improvements in BMI, waist circumference, and blood pressure. See NEJM 2023 / PubMed.

Type 2 Diabetes: In the Lancet Phase 2 trial, retatrutide reduced HbA1c by up to −2.16 percentage points at the highest doses, accompanied by a robust weight reduction (~17% at 36 weeks). The most frequent adverse events were gastrointestinal (nausea, reduced appetite), generally mild to moderate. See Lancet 2023 / PubMed.

Liver (MASLD): The Nature Medicine substudy reported a relative liver fat reduction of −81–82% at 8–12 mg doses, with normalization (<5%) in most participants and improvement in inflammation and liver function biomarkers. See Nature Medicine 2024 / PubMed.

Comparison with Semaglutide and Tirzepatide

Semaglutide (GLP-1 agonist) achieved ~15% mean weight loss over ~68 weeks; tirzepatide (GLP-1+GIP agonist) reached ~22.5% over ~72 weeks. Retatrutide, through additional glucagon receptor activation, achieved ~24% in 48 weeks. Although not head-to-head comparisons, these results show a progressive enhancement of efficacy across incretin-agonist generations, positioning retatrutide as a likely pharmacological evolution of tirzepatide.

Drug	Activated Receptors	Main Effects	Riduzione peso (durata)
Semaglutide	GLP-1	Satiety↑, delayed gastric emptying↓, improved glycemic control	~15% (≈68 weeks)*
Tirzepatide	GLP-1 + GIP	> Appetite↓, glucose↓, enhanced insulin response↑	~22,5% (≈72 weeks)*
Retatrutide	GLP-1 + GIP + glucagon	All of the above + increased energy expenditure↑; marked reduction in liver fat	~24% (48 weeks)

Values derived from different clinical studies (not head-to-head). Retatrutide data from NEJM 2023; tirzepatide and semaglutide from SURMOUNT and STEP trials.

Clinical status and registries

Retatrutide remains under clinical investigation. Multiple Phase 3 trials are ongoing in various populations (obesity, type 2 diabetes, weight maintenance, comorbid conditions). For official protocols, see:

References

Pepticore Aminos products are intended exclusively for research and laboratory use (Research Use Only). Not for human or animal consumption, nor for clinical or therapeutic use.

Peptide Technical Data

Product Name	Retatrutide
CAS Number	2381089-83-2
Sequence (Truncated)	His–Aib–Glu–Gly–Thr–Phe–Thr–Ser–Asp–Val–Ser–Ser–Tyr–Leu–Glu–Gly–Gln–Ala–Ala–Lys–Glu–Phe–Ile–Ala–Trp–Leu–Val–Arg–Gly–Arg–Gly–[modifications not publicly disclosed]
Molecular Formula	C₂₁₅H₃₄₀N₄₈O₆₄
Molecular Weight	~4710.55 g/mol
Purity	≥99% (HPLC validated)
Synthesis Method	Solid-phase peptide synthesis (SPPS)
Form	Lyophilized powder (1 vial)
Appearance	White to off-white lyophilized powder
Solubility	Soluble in sterile water or 1% acetic acid (~1–2 mg/mL typical)
Stability & Storage	−20°C stable up to 24 months; after reconstitution: 4°C ≤4 weeks or −20°C ≤6 months
Shipping Conditions	Ambient temperature during transit; store at −20°C upon receipt
Regulatory Status	Research use only; not for human consumption

Storage

Storage Instructions

All Pepticore Aminos products are manufactured using a lyophilization (freeze-drying) process, which ensures product stability during shipping for up to 3–4 months.

Once reconstituted (mixed with bacteriostatic water), the peptides should be stored in the refrigerator to maintain stability. After reconstitution, they remain stable for up to 30 days.

What is Lyophilization

Lyophilization is a dehydration process, also known as cryodesiccation, in which peptides are first frozen and then exposed to low pressure. Under these conditions, the water in the vial sublimates directly from solid to gas, leaving behind a stable, white crystalline structure (lyophilized peptide).

The white powder can be stored at room temperature until reconstitution with bacteriostatic water.

Storage After Delivery

Keep peptides cool and protected from light. For use within a few days, weeks, or months, simple refrigeration at a temperature of < 4 °C (39 °F) is sufficient.

Lyophilized peptides are generally stable at room temperature for several weeks or longer; if use is expected within a few weeks or months, this storage condition is acceptable.

Long-Term Storage

For periods of several months or years, storage in a −80 °C (−112 °F) freezer is recommended as the optimal solution to preserve peptide stability.

For more information on proper storage techniques, visit:
Peptide Storage Information

Disclaimer - For Research Use Only

The products offered by Pepticore Aminos are intended exclusively for research and laboratory use and are sold only to qualified professionals, institutions, or authorized entities. These products are not intended for human or veterinary consumption, nor for any application involving living organisms, including – but not limited to – diagnostic, therapeutic, or recreational purposes.

By making a purchase, the customer declares that:

they are a qualified professional or entity, possessing the necessary competence, training, and facilities for the safe handling of chemical reagents;
they will use the product in full compliance with all applicable local, national, and European Union laws and regulations;
they will adopt appropriate safety measures during all stages of handling, storage, and disposal.

Prohibited uses:

The product must not be used as an Active Pharmaceutical Ingredient (API) in the manufacturing or preparation of medicines intended for humans or animals;
Any direct administration or use on humans or animals is strictly prohibited;
Pepticore Aminos does not endorse or permit the use of its products for the production, testing, or development of illegal substances.

Regulatory compliance:

Pepticore Aminos does not claim or imply that its products are approved by the European Medicines Agency (EMA), the Food and Drug Administration (FDA), or any other regulatory authority. All information provided is for informational and scientific purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease.

Liability:

L’acquirente si assume ogni responsabilità per la manipolazione, conservazione e utilizzo del prodotto in condizioni sicure e conformi alla legge.
Pepticore Aminos non potrà essere ritenuta responsabile per danni diretti o indiretti derivanti da un uso improprio, dallo stoccaggio non corretto o da un utilizzo non autorizzato del prodotto.
Pepticore Aminos si riserva il diritto di rifiutare la vendita a qualsiasi individuo o ente sospettato di uso improprio dei propri prodotti.

In case of doubts regarding the safe and lawful use of the product, it is recommended to consult a qualified professional experienced in laboratory research.